The Medical Design & Outsourcing Medtech Big 100 ranking reveals a stagnation in R&D spending growth among the world’s largest medical device companies, following years of double-digit increases. Factors include rising material costs due to import taxes, potential U.S. recession risks, and federal funding cuts. While some companies like Johnson & Johnson MedTech and Stryker increased R&D investments, others like Medtronic and Siemens Healthineers reported declines. The slowdown raises concerns about future innovation and patient outcomes, with experts predicting increased M&A activity as companies seek external innovations.

The market for intravenous fluid monitoring devices is experiencing robust growth, projected to expand from $5.12 billion in 2024 to $5.59 billion in 2025 with a CAGR of 9.1%, and further to $7.84 billion by 2029 at a CAGR of 8.8%. This growth is driven by rising chronic diseases, an aging population, increased home healthcare services, advancements in remote monitoring, and integration of technologies like IoT and artificial intelligence. Home healthcare, including medical and non-medical services provided in private homes, is a key driver, with Public Health Scotland reporting over 37.7 million hours of Care at Home services in 2022/23. The market is segmented by product type, application, and end-user, with major players like B. Braun, Johnson & Johnson, and Medtronic forming strategic partnerships to enhance product capabilities and market reach. North America currently leads the market, while Asia-Pacific is expected to grow fastest in the forecast period.

Avanos Medical Inc (AVNS) reported 2% organic sales growth in Q2 2025, with net sales of $175 million, adjusted diluted EPS of $0.17, and adjusted EBITDA of $17 million. The company faced a $77 million non-cash impairment charge in the Pain Management and Recovery unit, while Specialty Nutrition Systems grew 5% organically and Radiofrequency Ablation (RFA) grew 14% year-over-year. The company divested its Hyaluronic Acid product line and maintained a $90 million cash balance, though free cash flow was negative $4 million. 2025 full-year revenue guidance is $665 million to $685 million, with $50 million in estimated tariff-related costs.

HTF Market Intelligence released a comprehensive global High Pressure Infusion Pump Market Study analyzing the industry from 2025 to 2032. The report projects a 12.10% CAGR, with the market expanding from $0.90 billion in 2025 to $2.20 billion in 2032. It covers market trends, regional analysis, and key players including Medtronic, Mindray, and Avanos Medical.

Avanos Medical has appointed Camille Chang Gilmore as its Chief Human Resources Officer, bringing over 25 years of HR leadership experience from diverse industries. She will lead global talent strategies, aligning with Avanos' focus on fostering an inclusive culture centered on employee well-being and patient care. Gilmore previously held roles at Boston Scientific and holds a bachelor’s in business management and an MBA.